Could GLP-1 Drugs Like Ozempic Help People Quit Smoking and Avoid Weight Gain at the Same Time?
Emerging evidence suggests GLP-1 receptor agonists may reduce nicotine cravings through brain reward pathways while simultaneously preventing post-cessation weight gain — but rigorous clinical trials are still needed.
Quick Facts
What This Study Found
The review synthesizes preclinical and limited clinical evidence showing that GLP-1 receptor agonists may address nicotine dependence through two mechanisms:
1. **Reduced nicotine cravings**: GLP-1 RAs modulate central reward pathways (mesolimbic dopamine system) that underlie nicotine's addictive properties, potentially reducing cravings and nicotine intake.
2. **Weight gain prevention**: The well-established appetite-suppressing and weight-loss effects of GLP-1 RAs could counteract the metabolic changes that follow nicotine withdrawal (increased caloric intake, reduced energy expenditure).
This dual mechanism could improve quit success rates while eliminating one of the primary psychological barriers to smoking cessation.
Key Numbers
How They Did This
This is a narrative review synthesizing evidence from preclinical animal studies, limited clinical trials, and pharmacological literature on GLP-1 receptor agonists' effects on nicotine dependence and post-cessation weight management.
Why This Research Matters
Smoking kills over 8 million people annually, and weight gain after quitting is both a health risk and a major deterrent to quitting. If GLP-1 agonists — already prescribed to millions for weight loss — can simultaneously address nicotine addiction, it could revolutionize smoking cessation and prevent relapse in a population that has been underserved by existing quit-smoking medications.
The Bigger Picture
This review reflects a broader trend of discovering that GLP-1 agonists affect far more than blood sugar and weight. Reports of reduced cravings for alcohol, nicotine, and other substances in patients taking these drugs have generated enormous public interest. If confirmed in rigorous trials, GLP-1 agonists could become the first medication class to simultaneously treat obesity, diabetes, cardiovascular disease, and addiction — a remarkably broad therapeutic profile.
What This Study Doesn't Tell Us
The human evidence base is very limited: small sample sizes, short follow-up periods, and reliance on preliminary or observational data. No large randomized controlled trials specifically testing GLP-1 RAs for smoking cessation have been completed. Potential side effects (nausea, pancreatitis risk) and the cost of GLP-1 drugs could limit real-world applicability. The narrative review format does not systematically assess study quality or risk of bias.
Questions This Raises
- ?Will ongoing randomized controlled trials confirm that GLP-1 agonists meaningfully improve smoking quit rates compared to existing medications like varenicline?
- ?At what dose and duration are GLP-1 agonists most effective for nicotine craving reduction — is it the same as for weight loss?
- ?Could GLP-1 agonists be combined with existing quit-smoking therapies (nicotine replacement, bupropion) for additive effects?
Trust & Context
- Key Stat:
- Dual-target potential GLP-1 agonists may address nicotine cravings through brain reward circuits while simultaneously preventing the weight gain that drives many smokers to relapse
- Evidence Grade:
- This is a narrative review based primarily on preclinical data and limited clinical observations. While the biological rationale is compelling, the lack of large randomized controlled trials means the evidence for GLP-1 agonists as smoking cessation aids remains preliminary.
- Study Age:
- Published in 2026, this review captures the current wave of interest in GLP-1 agonists' effects on addictive behaviors — a topic receiving enormous public and scientific attention.
- Original Title:
- GLP-1 receptor agonists for smoking cessation: a narrative review of weight management potential.
- Published In:
- Annals of medicine and surgery (2012), 88(3), 2373-2382 (2026)
- Authors:
- Ahmed, Ghazi Uddin(2), Zehra, Eiman, Rasheed, Sana, Akhtar, Syed Owais, Raza, Ahmed Asad, Mujaddadi, Khunsha, Samadi, Abedin
- Database ID:
- RPEP-14708
Evidence Hierarchy
Frequently Asked Questions
Can my doctor prescribe Ozempic or Wegovy to help me quit smoking?
Not yet — GLP-1 agonists are not approved for smoking cessation, and the evidence supporting this use is still preliminary. Some patients taking these drugs for weight loss or diabetes have reported reduced nicotine cravings, but randomized clinical trials are needed before doctors can officially recommend them for quitting smoking.
Why would a diabetes drug help with nicotine addiction?
GLP-1 receptors are found not only in the gut and pancreas but also in brain areas that control reward and motivation — the same circuits hijacked by nicotine. By modulating these reward pathways, GLP-1 drugs may reduce the 'pull' of nicotine. They also prevent weight gain, removing one of the biggest fears that keeps people smoking.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14708APA
Ahmed, Ghazi Uddin; Zehra, Eiman; Rasheed, Sana; Akhtar, Syed Owais; Raza, Ahmed Asad; Mujaddadi, Khunsha; Samadi, Abedin. (2026). GLP-1 receptor agonists for smoking cessation: a narrative review of weight management potential.. Annals of medicine and surgery (2012), 88(3), 2373-2382. https://doi.org/10.1097/MS9.0000000000004725
MLA
Ahmed, Ghazi Uddin, et al. "GLP-1 receptor agonists for smoking cessation: a narrative review of weight management potential.." Annals of medicine and surgery (2012), 2026. https://doi.org/10.1097/MS9.0000000000004725
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 receptor agonists for smoking cessation: a narrative r..." RPEP-14708. Retrieved from https://rethinkpeptides.com/research/ahmed-2026-glp1-receptor-agonists-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.